Tumor-stroma interaction increases CD147 expression in neoplastic B lymphocytes in chronic lymphocytic leukemia

Rodríguez, Cecilia; Gilardoni, Mónica Beatriz; Remedi, María Mónica; Sastre, Darío; Heller, Viviana; Pellizas, Claudia G.; Donadío, Ana Carolina

doi:10.1016/j.bcmd.2020.102405

Cited by 5 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that Basigin plays a significant role in TIE1-mediated cervical cancer progression, Basigin inhibitors may be effective for cervical cancer patients with high TIE1 expression. Currently, several types of Basigin inhibitors are under clinical trials 38 , 39 . Although few studies have focused on therapy targeting TIE1, a nanobody with high expression, good affinity, and specificity for TIE1 was recently developed to trigger TIE1-dependent inhibition of TIE2 phosphorylation and angiogenesis in endothelial cells 40 .…”

Section: Discussionmentioning

confidence: 99%

TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis

Liu,

Xie,

et al. 2024

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Background: Tyrosine kinase with immunoglobulin and EGF-like domains 1 (TIE1) is known as an orphan receptor prominently expressed in endothelial cells and participates in angiogenesis by regulating TIE2 activity. Our previous study demonstrated elevated TIE1 expression in cervical cancer cells. However, the role of TIE1 in cervical cancer progression, metastasis and treatment remains elusive. Methods: Immunohistochemistry staining for TIE1 and Basigin was performed in 135 human cervical cancer tissues. Overexpressing vectors and siRNAs were used to manipulate gene expression in tumor cells. Colony formation, wound healing, and transwell assays were used to assess cervical cancer cell proliferation and migration in vitro. Subcutaneous xenograft tumor and lung metastasis mouse models were established to examine tumor growth and metastasis. Co-Immunoprecipitation and Mass Spectrometry were applied to explore the proteins binding to TIE1. Immunoprecipitation and immunofluorescence staining were used to verify the interaction between TIE1 and Basigin. Cycloheximide chase assay and MG132 treatment were conducted to analyze protein stability. Results: High TIE1 expression was associated with poor survival in cervical cancer patients. TIE1 overexpression promoted the proliferation, migration and invasion of cervical cancer cells in vitro, as well as tumor growth and metastasis in vivo. In addition, Basigin, a transmembrane glycoprotein, was identified as a TIE1 binding protein, suggesting a pivotal role in matrix metalloproteinase regulation, angiogenesis, cell adhesion, and immune responses. Knockdown of Basigin or treatment with the Basigin inhibitor AC-73 reversed the tumor-promoting effect of TIE1 in vitro and in vivo. Furthermore, we found that TIE1 was able to interact with and stabilize the Basigin protein and stimulate the Basigin-matrix metalloproteinase axis. Conclusion: TIE1 expression in cervical cells exerts a tumor-promoting effect, which is at least in part dependent on its interaction with Basigin. These findings have revealed a TIE2-independent mechanism of TIE1, which may provide a new biomarker for cervical cancer progression, and a potential therapeutic target for the treatment of cervical cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis

Liu,

Xie,

et al. 2024

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

Expression Patterns of Cd90, Cd117, Cd123, and Cd147 in Mature B Cell Neoplasms

Zavelevich,

Shlapatska,

Philchenkov

et al. 2023

Oncology

View full text Add to dashboard Cite

Summary. Aim: to analyze the expression patterns of CD90, CD117, CD123, and CD147 on cells of the mature B-cell neoplasms, in particular marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) and the expression of CD147 on chronic lymphocytic leukemia (CLL) cells. Object and methods: the expression patterns of the surface antigens on the transformed B cells were analyzed in the peripheral blood samples of the MZL, MCL, and CLL patients (34 patients in total) by the flow cytometry using the monoclonal antibodies. Results: at least one of the antigens – CD90, CD117, or CD123 was expressed in 20.0–33.3% of MCL cases and 27.2–54.5% of MZL cases at the level ≥ 1% of the cells in the subpopulation of CD45-positive lymphoid cells. One MCL case demonstrated the high content of CD117-positive cells (31.0%) accompanied by CD90 expression on 3.8% of cells. The high content of the CD147-positive cells was found not only in MZL and MCL but also in CLL. Conclusion: a small fraction of cells of lymphoid neoplasms expresses several antigens of the leukemic stem cells and cells of the myeloid lineage. The ubiquitous pattern of CD147 expression on cells of these neoplasms has been demonstrated. The diagnostic and prognostic significance of the expression of the studied antigens remains unknown necessitating further clinical studies of the clinical features of these diseases taking into account the expression of the atypical markers.

show abstract

Expression Patterns of Cd90, Cd117, Cd123, and Cd147 in Continuous Cell Lines of Human Mature B-Cell Tumors

Zavelevich,

Shlapatska,

Philchenkov

2024

Oncology

View full text Add to dashboard Cite

Summary. Aim: to analyze expression patterns of CD90, CD117, CD123, and CD147 in vitro in different continuous lines of human mature B-cell neoplasms. Objects and methods: expression patterns of the surface antigens on cells of the continuous lines of Burkitt lymphoma (Namalwa and BJAB), Hodgkin lymphoma (КМ-Н2), and follicular lymphoma (Car-1) were analyzed by flow cytometry with monoclonal antibodies against CD90, CD117, CD123, and CD147. Results: BJAB and Namalwa cells did not express CD90 and CD123, while a small fraction of cells (less than 2%) was CD117-positive. КМ-Н2 and Сar-1 cells did not express any of three above mentioned antigens. The percentage of CD147-positive cells in continuous lines of human mature B-cell neoplasms amounted to 80–100%. Conclusions: CD117 expression in cell populations of Burkitt lymphoma continuous cell lines is rather rare. CD90 and CD123 are not expressed in all cell lines of human mature B-cell neoplasms under study. At the same time, ubiquitous pattern of CD147 has been evident.

show abstract

Tumor-stroma interaction increases CD147 expression in neoplastic B lymphocytes in chronic lymphocytic leukemia

Cited by 5 publications

References 42 publications

TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis

TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis

Expression Patterns of Cd90, Cd117, Cd123, and Cd147 in Mature B Cell Neoplasms

Expression Patterns of Cd90, Cd117, Cd123, and Cd147 in Continuous Cell Lines of Human Mature B-Cell Tumors

Contact Info

Product

Resources

About